Replies to post #129506 on Anavex Life Sciences Corp (AVXL)

[imho]

Solanezumab drugmaker Eli Lilly reported the top-line results of the highly anticipated EXPEDITION3 trial in a press release last month. There was an 11% slower decline in disease progression for those on the drug, but the difference on the ADAS-Cog14 wasn't significant at 80 weeks (P=0.095).

Compare that performance over 80 weeks to the Anavex sub-group over 109 weeks.

Yes indeed. The Lilly drug is out to pasture, but Biogen's Aducanumab is the current poster child for the hypothesis and it is soaking up the media coverage and mind share. I suggest people DD on the Biogen results recently, like I have. The Anavex results are much more encouraging. The only negative thing with the Anavex presentation recently, was the absence of the entire cohort population for the entire 109 weeks. Such data, even showing poor performance, would have been better than not having the data. Hopefully it will be released in due time.

IMHO